8.91
0.79%
0.07
시간 외 거래:
8.90
-0.010
-0.11%
전일 마감가:
$8.84
열려 있는:
$8.9
하루 거래량:
802.91K
Relative Volume:
1.07
시가총액:
$322.89M
수익:
-
순이익/손실:
$-117.26M
주가수익비율:
-2.6837
EPS:
-3.32
순현금흐름:
$-99.96M
1주 성능:
-26.12%
1개월 성능:
-14.98%
6개월 성능:
-27.85%
1년 성능:
-11.69%
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
900 MIDDLEFIELD ROAD, REDWOOD CITY
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-09 | 개시 | Edward Jones | Buy |
2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
2024-09-27 | 업그레이드 | Truist | Hold → Buy |
2024-08-29 | 개시 | CapitalOne | Overweight |
2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-02-06 | 개시 | Truist | Buy |
2023-07-27 | 개시 | Scotiabank | Sector Outperform |
2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
2023-05-12 | 개시 | Barclays | Overweight |
2023-03-29 | 재확인 | Oppenheimer | Outperform |
2023-03-28 | 재확인 | H.C. Wainwright | Buy |
2023-02-24 | 개시 | Citigroup | Buy |
2022-06-02 | 재개 | H.C. Wainwright | Buy |
2022-01-12 | 개시 | H.C. Wainwright | Buy |
2021-12-17 | 개시 | Oppenheimer | Outperform |
2021-05-11 | 개시 | JP Morgan | Overweight |
2021-05-11 | 개시 | Jefferies | Buy |
2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
Biomea Fusion, Inc. Reveals Preclinical Data on Icovamenib and BMF-650 in Recent SEC Filing - Defense World
Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook - Investing.com India
Biomea Fusion FY2024 EPS Estimate Raised by HC Wainwright - Defense World
Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Biomea Fusion stock PT raised by Piper Sandler, citing pipeline potential - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Unveils Promising Diabetes Treatment Innovations - TipRanks
Biomea Fusion Reports Q3 2024 Financial Results - MSN
Biomea Fusion Presents Preclinical Data Showing Icovamenib - GlobeNewswire
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate - Yahoo Finance
Barclays Forecasts Strong Price Appreciation for Biomea Fusion (NASDAQ:BMEA) Stock - MarketBeat
Biomea Awaits 2 Data Readouts Of Diabetes StudiesCan The Stock Get Its Mojo Back? - RTTNews
Biomea Fusion (NASDAQ:BMEA) Announces Earnings Results - MarketBeat
Biomea Fusion price target raised to $11 from $9 at Barclays - TipRanks
Biomea Fusion reports Q3 EPS (91c), consensus (95c) - TipRanks
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewswire
Biomea Fusion options imply 6.1% move in share price post-earnings - TipRanks
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Brokerages - Defense World
(BMEA) Technical Data - Stock Traders Daily
Biomea Fusion shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia
Biomea Fusion's (BMEA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Biomea Fusion shares maintain Buy rating from H.C. Wainwright - Investing.com
Exchange Traded Concepts LLC Acquires 8,079 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion's icovamenib gets global and US naming approval - Investing.com India
Biomea Fusion's icovamenib gets global and US naming approval By Investing.com - Investing.com South Africa
Biomea Fusion announces approval of ‘icovamenib’ as INN for BMF-219 - TipRanks
Biomea Fusion Announces Approval of 'icovamenib” as International Nonproprietary Name for BMF-219 - The Manila Times
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219 - GlobeNewswire
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
(BMEA) Investment Analysis and Advice - Stock Traders Daily
Griffin Asset Management Inc. Purchases 57,180 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-21 - The Manila Times
Biomea Fusion to Host Conference Call and Webcast on - GlobeNewswire
Marshall Wace LLP Sells 3,900 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Squarepoint Ops LLC Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat
Investigation Launched into Biomea Fusion Securities - Bit Perfect Solutions
Biomea Fusion (NASDAQ:BMEA) Upgraded at EF Hutton Acquisition Co. I - MarketBeat
Biomea Fusion shares recieve Buy rating from EF Hutton - Investing.com
Biomea Fusion shares recieve Buy rating from EF Hutton By Investing.com - Investing.com UK
Biomea Fusion initiated with a Buy at EF Hutton - TipRanks
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) - The Manila Times
Biomea Fusion to Present at the 1st Annual Asian Conference - GlobeNewswire
Point72 Asia Singapore Pte. Ltd. Acquires New Stake in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Renaissance Technologies LLC Purchases Shares of 329,106 Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Renaissance Technologies LLC Purchases New Shares in Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):